Disease · MONDO_0005629
Acanthamoeba keratitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Acanthamoeba keratitis. Diseases, record MONDO_0005629. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005629
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Acanthameba keratitis, Acanthamoeba caused keratitis, Acanthamoeba keratitis (disorder), keratitis, Acanthamoeba
- Open Targets
Drugs20
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| POLIHEXANIDE | CHEMBL2106939 | Small molecule | Approval | EMA Human Drugs | 3 | 2 | 2 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| BETAMETHASONE DIPROPIONATE | CHEMBL1200384 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| BETAMETHASONE SODIUM PHOSPHATE | CHEMBL1200762 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CHLORHEXIDINE GLUCONATE | CHEMBL4297088 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| METHYLPREDNISOLONE ACETATE | CHEMBL1364144 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| MOXIFLOXACIN | CHEMBL32 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NATAMYCIN | CHEMBL1200656 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 20
See all 20 drugsTargets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 |
Source Drugs and targets
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05110001 | Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction | Phase 3 | 330 | 2026-01-30 | Acanthamoeba Keratitis, Fungal Keratitis | CHLORHEXIDINE GLUCONATE, MOXIFLOXACIN, NATAMYCIN, ROSE BENGAL FREE ACID | Its record names the disease | ClinicalTrials.gov |
| NCT03274895 | Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis | Phase 3 | 135 | 2023-08-02 | Acanthamoeba Keratitis | POLIHEXANIDE, PROPAMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT03484507 | Parasitic Ulcer Treatment Trial Pilot | Phase 2 | 49 | Acanthamoeba Keratitis | CHLORHEXIDINE, POVIDONE-IODINE, PREDNISOLONE SODIUM PHOSPHATE | Its record names the disease | ClinicalTrials.gov | |
| NCT07195864 | Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain. | 23 | Acanthamoeba Keratitis | POLIHEXANIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): deaths from any cause | 1 of 165 | 0 of 165 | 330 | NCT05110001 | Trial comparisons |
| Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): serious adverse events | 31 of 165 | 36 of 165 | 330 | NCT05110001 | Trial comparisons |
| PHMB 0.08% Plus Placebo vs PHMB 0.02% Plus Propamidine 0.1%: deaths from any cause | 0 of 69 | 0 of 65 | 134 | NCT03274895 | Trial comparisons |
| PHMB 0.08% Plus Placebo vs PHMB 0.02% Plus Propamidine 0.1%: serious adverse events | 0 of 69 | 0 of 65 | 134 | NCT03274895 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005629
GET https://conductscience.org/api/diseases/v1/MONDO_0005629/drugs